CA3260373A1 - Agents de dégradation de bcl6 macrocycliques - Google Patents

Agents de dégradation de bcl6 macrocycliques

Info

Publication number
CA3260373A1
CA3260373A1 CA3260373A CA3260373A CA3260373A1 CA 3260373 A1 CA3260373 A1 CA 3260373A1 CA 3260373 A CA3260373 A CA 3260373A CA 3260373 A CA3260373 A CA 3260373A CA 3260373 A1 CA3260373 A1 CA 3260373A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
methyl
pct
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3260373A
Other languages
English (en)
Inventor
Lyn Howard Jones
Huang Huang
Yingpeng Liu
Jianwei Che
Nikki Kong
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3260373A1 publication Critical patent/CA3260373A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés, des compositions et des méthodes de traitement de maladies et de troubles qui impliquent une activité aberrante du lymphome à cellules B 6 (BCL6).
CA3260373A 2022-08-09 2023-08-08 Agents de dégradation de bcl6 macrocycliques Pending CA3260373A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263396381P 2022-08-09 2022-08-09
US63/396,381 2022-08-09
US202263432580P 2022-12-14 2022-12-14
US63/432,580 2022-12-14
US202363465584P 2023-05-11 2023-05-11
US63/465,584 2023-05-11
PCT/US2023/029714 WO2024035688A1 (fr) 2022-08-09 2023-08-08 Agents de dégradation de bcl6 macrocycliques

Publications (1)

Publication Number Publication Date
CA3260373A1 true CA3260373A1 (fr) 2024-02-15

Family

ID=89852399

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3260373A Pending CA3260373A1 (fr) 2022-08-09 2023-08-08 Agents de dégradation de bcl6 macrocycliques

Country Status (15)

Country Link
EP (1) EP4568946A1 (fr)
JP (1) JP2025526656A (fr)
KR (1) KR20250044657A (fr)
CN (1) CN119585240A (fr)
AU (1) AU2023323799A1 (fr)
CA (1) CA3260373A1 (fr)
CL (1) CL2025000232A1 (fr)
CO (1) CO2025002627A2 (fr)
CR (1) CR20250039A (fr)
DO (1) DOP2025000020A (fr)
IL (1) IL317937A (fr)
JO (1) JOP20250033A1 (fr)
MX (1) MX2025001324A (fr)
PE (1) PE20250841A1 (fr)
WO (1) WO2024035688A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008066887A2 (fr) * 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Inhibiteurs du gène bcl6 à petite molécule
JP2017533922A (ja) * 2014-11-06 2017-11-16 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 移植片対宿主病（ｇｖｈｄ）のためのクロマチン構造を調節する組成物の使用
JP6999688B2 (ja) * 2016-12-13 2022-02-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｌ６阻害剤としての新規の６－アミノキノリノン化合物および誘導体
US11439635B2 (en) * 2019-07-30 2022-09-13 Northwestern University B cell lymphoma 6 protein (BCL6) as a target for treating diabetes mellitus and non-alcoholic fatty liver disease

Also Published As

Publication number Publication date
CO2025002627A2 (es) 2025-06-16
KR20250044657A (ko) 2025-04-01
CR20250039A (es) 2025-08-22
PE20250841A1 (es) 2025-03-21
JOP20250033A1 (ar) 2025-02-06
IL317937A (en) 2025-02-01
AU2023323799A1 (en) 2025-01-16
WO2024035688A1 (fr) 2024-02-15
CL2025000232A1 (es) 2025-04-04
MX2025001324A (es) 2025-03-07
CN119585240A (zh) 2025-03-07
EP4568946A1 (fr) 2025-06-18
DOP2025000020A (es) 2025-04-08
JP2025526656A (ja) 2025-08-15

Similar Documents

Publication Publication Date Title
AU2018255300B2 (en) Bicyclic compounds and their use in the treatment of cancer
CA3216163A1 (fr) Composes carboxy-benzimidazoles modulateurs du glp-1r
WO2023025116A1 (fr) Dérivé hétérocyclique, son procédé de préparation et son utilisation en médecine
CN114728918A (zh) Rip1抑制性化合物及其制备和使用方法
CN115611898A (zh) 四环类衍生物、其制备方法及其在医药上的应用
KR102834593B1 (ko) 면역조절 화합물
KR20110132564A (ko) 히스타민 ｈ3 역 작용제 및 길항제, 및 이의 사용 방법
CA2940918C (fr) Derives 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine substitues et derives 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine utilises comme inhibiteurs de ros1
AU2010237859A1 (en) Fused pyrrolopyridine derivative
AU2021227907A1 (en) Potent and selective degraders of ALK
KR20210049895A (ko) 고 활성 sting 단백질 작용제 화합물
CN113164475A (zh) Dyrk1a的大环抑制剂
KR102943035B1 (ko) Ripk2의 티에노피리딘 억제제
US20250074890A1 (en) Cyanopyridine and cyanopyrimidine bcl6 degraders
CA3163933A1 (fr) Antagonistes du recepteur m4 d'acetylcholine muscarinique
JP2024520395A (ja) 置換される縮合二環式大環状化合物および関連のある治療方法
CA3180717A1 (fr) Hydropyrroles substitues condenses utilises en tant qu'antagonistes du recepteur muscarinique m4 de l'acetylcholine
EP4562014A2 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
JP2025531863A (ja) ヘテロ二官能性化合物及び疾患の治療方法
WO2023204308A1 (fr) Dérivé d'oxazépine
AU2023323799A1 (en) Macrocyclic bcl6 degraders
EA053244B1 (ru) Макроциклические деградаторы bcl6
WO2024086094A1 (fr) Agents de dégradation de bcl6 à petites molécules contenant une alkylamine
US20260130907A1 (en) Alkylamine-containing small molecule degraders of bcl6
EP4558487A1 (fr) Agents de dégradation de lymphome à cellules b 6 (bcl6) de quinoxalinedione et de pyrido [2, 3-bjpyrazine -2, 3-dione et leurs utilisations

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241220

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250318

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250318

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250318